Analysts' ratings for BioNTech BNTX over the last quarter vary from bullish to bearish, as provided by 17 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 9 | 1 | 6 | 1 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 3 | 0 | 0 |
2M Ago | 6 | 1 | 3 | 0 | 0 |
3M Ago | 2 | 0 | 0 | 1 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, a high estimate of $150.00, and a low estimate of $91.00. This upward trend is apparent, with the current average reflecting a 19.85% increase from the previous average price target of $106.41.
Analyzing Analyst Ratings: A Detailed Breakdown
The analysis of recent analyst actions sheds light on the perception of BioNTech by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Chris Shibutani | Goldman Sachs | Raises | Buy | $137.00 | $90.00 |
Yaron Werber | TD Cowen | Lowers | Hold | $122.00 | $132.00 |
Yaron Werber | TD Cowen | Lowers | Hold | $122.00 | $132.00 |
Jessica Fye | JP Morgan | Lowers | Neutral | $124.00 | $125.00 |
Yifeng Liu | HSBC | Raises | Buy | $136.00 | $97.00 |
Robert Burns | HC Wainwright & Co. | Raises | Buy | $150.00 | $113.00 |
Terence Flynn | Morgan Stanley | Raises | Overweight | $145.00 | $93.00 |
Emmanuel Papadakis | Deutsche Bank | Raises | Buy | $150.00 | $95.00 |
Eliana Merle | UBS | Raises | Neutral | $131.00 | $97.00 |
Akash Tewari | Jefferies | Raises | Buy | $150.00 | $96.00 |
Jessica Fye | JP Morgan | Raises | Neutral | $125.00 | $91.00 |
Tazeen Ahmad | B of A Securities | Raises | Buy | $150.00 | $125.00 |
Robert Burns | HC Wainwright & Co. | Maintains | Buy | $113.00 | $113.00 |
Akash Tewari | Jefferies | Raises | Hold | $96.00 | $90.00 |
Robert Burns | HC Wainwright & Co. | Maintains | Buy | $113.00 | $113.00 |
Robert Burns | HC Wainwright & Co. | Maintains | Buy | $113.00 | $113.00 |
Jessica Fye | JP Morgan | Lowers | Underweight | $91.00 | $94.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BioNTech. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BioNTech compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for BioNTech's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of BioNTech's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on BioNTech analyst ratings.
Discovering BioNTech: A Closer Look
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
BioNTech's Economic Impact: An Analysis
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining BioNTech's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 39.04% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: BioNTech's net margin excels beyond industry benchmarks, reaching 15.91%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): BioNTech's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.04% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): BioNTech's ROA stands out, surpassing industry averages. With an impressive ROA of 0.89%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.